22nd Century Applauds FDA Proposal to Mandate Reduced Nicotine Content in Cigarettes
22nd Century Applauds FDA Proposal to Mandate Reduced Nicotine Content in Cigarettes
Recent FDA Action Advances Policy Proposal That Originated During First Trump Administration and Continued to Progress Under Biden Administration
FDA最近的行動推進了起源於特朗普第一屆政府期間並在拜登政府領導下繼續取得進展的政策提案
Mocksville, North Carolina--(Newsfile Corp. - December 12, 2024) - 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company that is leading the fight against nicotine and believes smokers should have a choice about their nicotine consumption, today announced that it applauds action by the U.S. Food and Drug Administration to advance its long-standing proposal mandating a drastic reduction in the amount of nicotine in cigarettes, a cornerstone goal of public health experts seeking to reduce the harms of smoking.
北卡羅來納州莫克斯維爾--(Newsfile Corp.,2024年12月12日)——22世紀集團公司(納斯達克股票代碼:XXII)是一家領導反尼古丁鬥爭並認爲吸菸者應該對尼古丁消費有選擇權的菸草製品公司,今天宣佈,它讚揚美國食品藥品監督管理局採取行動,推進其要求大幅減少香菸中尼古丁含量的長期提案,這是尋求減少吸菸危害的公共衛生專家的基石目標。
"We are excited to see definitive action by the FDA intended to advance its scientifically backed reduced nicotine content mandate for cigarette products, a non-partisan proposal that actually began moving forward during the first Trump administration and continued its progress during the Biden administration," said Larry Firestone, Chief Executive Officer of 22nd Century Group.
22世紀集團首席執行官拉里·費爾斯通表示:「我們很高興看到美國食品藥品管理局採取明確行動,旨在推進其有科學依據的菸草製品降低尼古丁含量的規定,這是一項無黨派的提案,實際上是在特朗普第一屆政府執政期間開始向前推進,並在拜登執政期間繼續取得進展。」
"22nd Century has played a pivotal role in this effort following 26 years of research and product development as a key supplier for reduced nicotine content research cigarettes used in the numerous federally funded studies to generate a massive body of scientific evidence in support of this policy. 22nd Century also has the first and only FDA authorized reduced nicotine content cigarette designed specifically to reduce the harms of smoking."
「22nd Century作爲降低尼古丁含量的研究香菸的主要供應商,在這項工作中發揮了關鍵作用。研究捲菸在衆多聯邦資助的研究中使用,以產生大量支持該政策的科學證據。22nd Century還擁有第一支也是唯一一支經美國食品藥品管理局批准的專爲減少吸菸危害而設計的降低尼古丁含量的香菸。」
"VLN reduced nicotine content cigarettes from 22nd Century, which are available in thousands of stores across the country, have shown that this product can be an important tool for adult smokers seeking to control their nicotine intake. We are now in the process of launching additional products, including VLN SKUs within key customer brand families, as part of our drive to expand the distribution of reduced nicotine content cigarettes manufactured by 22nd Century. Adding VLN within other brand families is a straightforward way to reduce our time to market, increase consumer awareness and expand the VLN footprint.
“來自22nd Century的VLN降低尼古丁含量的香菸在全國數千家商店有售,這表明該產品可以成爲尋求控制尼古丁攝入量的成年吸菸者的重要工具。我們現在正在推出更多產品,包括主要客戶品牌家族中的VLN SKU,這是我們擴大22nd Century生產的低尼古丁含量香菸分銷的努力的一部分。在其他品牌家族中添加VLN是縮短上市時間、提高消費者知名度並擴大VLN足跡的直接方法。
"With still almost half a million premature deaths in the U.S. attributed to smoking each year, we fully support the FDA in advocating for the significant potential harm reduction that could come from a reduced nicotine content cigarette mandate."
「在美國,每年仍有近50萬人因吸菸而過早死亡,我們完全支持美國食品藥品管理局倡導降低香菸的尼古丁含量可能會帶來顯著的潛在危害。」
About 22nd Century Group, Inc.
關於 22nd Century Group, Inc
22nd Century Group is the pioneering nicotine harm reduction company in the tobacco industry enabling smokers to take control of their nicotine consumption.
22nd Century Group 是菸草行業減少尼古丁危害的先驅公司,使吸菸者能夠控制他們的尼古丁消費。
We created our flagship product, the VLN cigarette, to give traditional cigarette smokers an authentic and familiar alternative that helps them take control of their nicotine consumption. VLN cigarettes have 95% less nicotine than the traditional cigarette and have been proven to greatly reduce nicotine consumption. Instead of offering new ways of delivering nicotine to addicted smokers, we offer smokers the option to take control of their nicotine consumption and make informed and more productive choices, including the choice to avoid addictive levels of nicotine altogether.
我們開發了我們的旗艦產品 VLN 香菸,爲傳統吸菸者提供一種真實而熟悉的替代品,幫助他們 控制他們的尼古丁消費。VLN香菸的尼古丁含量比傳統香菸低95%,並且已被證明可以大大減少尼古丁的消費。我們沒有提供向成癮的吸菸者提供尼古丁的新方法,而是爲吸菸者提供控制尼古丁消費,做出明智和更有成效的選擇,包括選擇完全避免尼古丁成癮水平。
Our wholly owned subsidiaries include a leading cigarette manufacturer that produces all VLN products and provides turnkey contract manufacturing for other tobacco brands both domestically and internationally. The 60,000 square foot facility in Mocksville, North Carolina has the capacity to produce more than 45 million cartons of combusted tobacco products annually with additional space for expansion.
我們的全資子公司包括一家領先的捲菸製造商,該公司生產所有VLN產品,併爲國內和國際上的其他菸草品牌提供一站式合同製造。這座位於北卡羅來納州莫克斯維爾的佔地60,000平方英尺的工廠每年可生產超過4500萬箱的燃燒菸草製品,還有額外的擴建空間。
Our proprietary reduced nicotine tobacco blends are made possible by comprehensive and patented technologies that regulate nicotine biosynthesis activities in the tobacco plant, resulting in full flavor and high yield with 95% less nicotine. Our extensive patent portfolio has been developed to ensure we have the only low nicotine combustible cigarette in the United States and critical international markets.
我們的專利技術使我們專有的還原尼古丁菸草混合物成爲可能,這些技術可調節菸草植物中的尼古丁生物合成活動,從而在尼古丁減少95%的情況下獲得飽滿的風味和高產量。我們開發了廣泛的專利組合,以確保我們擁有美國和關鍵國際市場上唯一的低尼古丁可燃香菸。
VLN and Helps You Smoke Less are registered trademarks of 22nd Century Limited LLC.
VLN 和 Helps You Smoke Less 是 22 世紀有限責任公司的註冊商標。
Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.
要了解更多,請訪問 xxiicentury.com,開啓 X(前身爲 Twitter),開啓 領英,等等 優酷.
Learn more about VLN at tryvln.com.
要了解有關 VLN 的更多信息,請訪問 tryvln.com.
Cautionary Note Regarding Forward-Looking Statements
關於前瞻性陳述的警示說明
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024, and in the Company's Quarterly Reports filed on May 15, 2024 and August 13, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.
除歷史信息外,本新聞稿中包含的所有陳述、預期和假設均爲前瞻性陳述,包括但不限於我們的全年業務展望。前瞻性陳述通常包含 「預測」、「相信」、「考慮」、「繼續」、「可能」、「估計」、「預期」、「探索」、「預見」、「目標」、「指導」、「打算」、「可能」、「計劃」、「潛在」、「預測」、「初步」、「可能」、「項目」、「有希望」、「尋求」 等術語、” 「應該」、「將」、「將」 和類似的表達。前瞻性陳述包括但不限於有關以下方面的陳述:(i)我們的成本削減計劃,(ii)我們對監管執法的預期,包括我們獲得新法規豁免的能力,(iii)我們的財務和經營業績以及(iv)我們對業務中斷保險索賠的預期。實際結果可能與前瞻性陳述中的明示或隱含結果存在重大差異。公司於2024年3月28日提交的10-k表年度報告以及公司於2024年5月15日和2024年8月13日提交的季度報告中的 「風險因素」 中列出了可能導致實際業績出現重大差異的重要因素。本新聞稿中提供的所有信息均爲截至本新聞稿發佈之日,除非法律要求,否則公司不承擔任何義務也不打算更新這些前瞻性陳述。
Investor Relations & Media Contact
投資者關係與媒體聯繫人
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200
馬特·克雷普斯
投資者關係
22 世紀集團
mkreps@xxiicentury.com
214-597-8200